Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

zenocutuzumab-zbco

View Patient Information
A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab-zbco may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab-zbco is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER2 x Anti-HER3 bispecific monoclonal antibody MCLA-128
anti-HER2/Anti-HER3 bispecific monoclonal antibody MCLA-128
zenocutuzumab
US brand name:Bizengri
Code name:MCLA 128
MCLA-128
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search